Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth

Oncogene

Volumn 34, Issue 27, 2015, Pages 3493-3503

  De Simone, V ^a   Franze E ^a   Ronchetti, G ^a   Colantoni, A ^a   Fantini, M C ^a   Di Fusco, D ^a   Sica, G S ^a   Sileri, P ^a   Macdonald, T T ^b   Pallone, F ^a   Monteleone, G ^a   Stolfi, C ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CELL CULTURE; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; TH17 CELL; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKINS; MICE; MICE, TRANSGENIC; NF-KAPPA B; STAT3 TRANSCRIPTION FACTOR; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85028276122     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/ONC.2014.286     Document Type: Article

References (46)

1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366–378.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526–535.
4. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103–113.
5. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491: 259–263.
6. Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim HY. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012; 33: 931–936.
7. Jauch D, Martin M, Schiechl G, Kesselring R, Schlitt HJ, Geissler EK et al. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 2011; 60: 1678–1686.
8. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210: 917–931.
9. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560–570.
10. Stolfi C, Rizzo A, Franze E, Rotondi A, Fantini MC, Sarra M et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 2011; 208: 2279–2290.
11. Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes Implications for cancer surveillance and immunotherapy. Oncoimmunology 2012; 1: 717–725.
12. Monteleone G, Pallone F, Stolfi C. The dual role of inflammation in colon carcinogenesis. Int J Mol Sci 2012; 13: 11071–11084.
13. Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58: 2832–2837.
14. Senik A, Stefanos S, Kolb JP, Lucero M, Falcoff E. Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Paris) 1980; 131C: 349–361.
15. Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in IFNgammamediated anti-tumor activity. Semin Cancer Biol 2000; 10: 113–123.
16. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129–134.
17. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960–1964.
18. Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 2014; 40: 140–152.
19. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G et al. GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40: 785–800.
20. Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014; 40: 772–784.
21. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254–258.
22. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 5540–5544.
23. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 2011; 71: 5601–5605.
24. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.
25. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263–1271.
26. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11–19.
27. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT et al. Orally bioavailable smallmolecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012; 109: 9623–9628.
28. Issa AY, Volate SR, Muga SJ, Nitcheva D, Smith T, Wargovich MJ. Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis 2007; 28: 1978–1984.
29. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013; 24: 257–271.
30. Yamane H, Paul WE. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev 2013; 252: 12–23.
31. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655–669.
32. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121–1133.
33. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485–517.
34. Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol 2009; 183: 7161–7168.
35. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283–293.
36. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–296.
37. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cellcycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91–102.
38. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758–6780.
39. Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers (Basel) 2014; 6: 897–925.
40. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41–51.
41. Caprioli F, Sarra M, Caruso R, Stolfi C, Fina D, Sica G et al. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 2008; 180: 1800–1807.
42. Yeste A, Mascanfroni ID, Nadeau M, Burns EJ, Tukpah AM, Santiago A et al. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun 2014; 5: 3753.
43. Wang K, Grivennikov SI, Karin M. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis2013; 72(Suppl 2): ii100–ii103.
44. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112: 1169–1178.
45. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC et al. Cyclooxygenase-2-dependent and-independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008; 75: 668–676.
46. Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA et al. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut 2005; 54: 950–954.